The innate immune system represents the body’s first line of defense against infection and cellular distress, and few of its molecular machines have attracted as much attention in recent years as inflammasomes and their close relatives, the PANoptosomes. A new review published in Cell Research examines how structural biology and mechanistic studies have transformed our understanding of these multiprotein signaling complexes, offering a detailed account of how innate immune sensors recognize danger signals, assemble supramolecular platforms, and ultimately trigger inflammatory cell death. The work arrives at a moment when therapeutic strategies targeting these pathways are moving rapidly from the laboratory toward the clinic, making a synthesis of structural and mechanistic knowledge particularly timely.
Inflammasomes are cytosolic signaling complexes assembled by pattern recognition receptors in response to a wide array of danger-associated and pathogen-associated molecular patterns. Among the best characterized is the NLRP3 inflammasome, which can be activated by an extraordinary diversity of stimuli, ranging from extracellular ATP and crystalline substances such as monosodium urate to perturbations in cellular homeostasis including mitochondrial dysfunction and ionic flux. Structural studies, notably cryo-electron microscopy analyses, have revealed that NLRP3 oligomerizes into a large ring-like platform that recruits the adaptor protein ASC through pyrin domain interactions. ASC in turn nucleates the polymerization of procaspase-1 filaments through its caspase recruitment domain, creating a branched, star-shaped assembly that has become iconic in the field of innate immunity.
The review emphasizes how this hierarchical assembly process, in which a receptor seeds adaptor polymerization which then seeds effector activation, is a recurring architectural principle across inflammasome families. DNA-sensing receptors such as AIM2 and the Pyrin family of receptors, as well as the more recently described sensors like NLRP1 and CARD8, all converge on the same downstream machinery despite recognizing fundamentally different ligands. This convergence explains how a limited set of adaptor and effector molecules can translate an enormous diversity of upstream danger signals into a uniform cellular response: the activation of inflammatory caspases, cleavage of the cytokine precursors pro-interleukin-1 beta and pro-interleukin-18, and induction of a lytic form of cell death known as pyroptosis.
Pyroptosis itself has been structurally dissected at the level of its executioner, gasdermin D. Activated inflammatory caspases cleave gasdermin D to release an N-terminal fragment that oligomerizes into membrane pores, causing osmotic lysis and the release of intracellular contents, including mature interleukin-1 beta. Recent structures of gasdermin pores have clarified how the positively charged face of the oligomer interacts with membrane lipids and how pore formation is regulated. This level of mechanistic detail has direct pharmacological implications, because small molecules that block gasdermin pore formation or inflammasome assembly could dampen pathological inflammation in conditions as varied as gout, atherosclerosis, type 2 diabetes, inflammatory bowel disease, and neurodegenerative disease, all of which have been linked to excessive inflammasome activity.
Beyond canonical inflammasomes, the review devotes substantial attention to PANoptosis, a recently articulated form of inflammatory programmed cell death that integrates features of pyroptosis, apoptosis, and necroptosis within a single, coordinated complex termed the PANoptosome. Unlike a classical inflammasome, a PANoptosome contains components from multiple cell death pathways simultaneously, including Z-DNA-binding protein 1, or ZBP1, which senses Z-form nucleic acids generated during viral infection, together with receptor-interacting protein kinases and other death-domain proteins. Structural and biochemical studies suggest that these complexes assemble through a web of homotypic and heterotypic domain interactions, creating a platform capable of activating multiple death effector machineries in parallel and amplifying inflammatory signaling to a degree that neither pathway could achieve alone.
ZBP1 has emerged as a particularly instructive example of how structural insights inform PANoptosome biology. Its two Z-nucleic acid binding domains recognize the unusual left-handed conformation of Z-DNA and Z-RNA, which accumulates in cells infected with viruses such as influenza A. Upon ligand binding, ZBP1 engages RIPK3 through RHIM domain interactions, and in certain contexts also recruits NLRP3 and ASC, thereby coupling viral sensing directly to necroptosis, pyroptosis, and cytokine release. Mutations that disrupt these interactions protect mice from lethal influenza-associated inflammation, underscoring the in vivo importance of this pathway and highlighting RHIM-mediated interactions as a potential drug target in severe viral pneumonia and other contexts of pathogenic inflammation.
One of the central themes of the review is that autoinhibition is a universal feature of innate immune sensors, reflecting the danger of accidental self-destruction if these potent inflammatory pathways are triggered spuriously. NLRP3, for example, is held in an inactive conformation by its LRR domain folding back onto the nucleotide-binding domain, a constraint released through a multi-step activation process involving NEK7 binding, deubiquitination, and translocation to the Golgi or endosomal membranes. Similar autoinhibitory mechanisms govern NLRP1, which releases its inhibitory function upon proteasomal degradation of an N-terminal regulatory segment, and pyrin, which is restrained by phosphorylation-dependent sequestration through binding to 14-3-3 proteins. Structural biology has provided atomic-level explanations for how disease-associated mutations, including those causing cryopyrin-associated periodic syndromes and familial Mediterranean fever, destabilize these autoinhibited states and drive constitutive inflammasome activation.
The therapeutic implications of this structural knowledge are considerable and span several classes of intervention. Direct inhibitors of NLRP3, such as MCC950 and its derivatives, have demonstrated efficacy in preclinical models of numerous inflammatory diseases and are progressing through clinical evaluation. Second-generation approaches include compounds that block ASC speck formation, inhibitors of inflammatory caspases, gasdermin D antagonists designed to prevent pore formation, and agents targeting upstream cytokine signaling through blockade of interleukin-1 family receptors. For PANoptosome-driven diseases, particularly severe viral infections and certain hereditary autoinflammatory syndromes, strategies that interrupt specific protein-protein interfaces, such as the RHIM-dependent interaction between ZBP1 and RIPK3, represent an emerging frontier. The review argues that structural data, by revealing precisely where and how these complexes assemble, will be indispensable for the rational design of such inhibitors.
Challenges nonetheless remain substantial. Inflammasome components are large, flexible, and often membrane-associated, complicating structural determination of full assemblies in physiologically relevant states. Much of the available structural information derives from isolated domains, truncated constructs, or oligomers assembled in vitro, and bridging the gap between these reductionist structures and the behavior of intact complexes in living cells remains a priority. Moreover, the redundancy and interconnection of inflammatory cell death pathways mean that blocking one arm may simply redirect signaling through another, arguing for combination approaches informed by a systems-level understanding of PANoptosome architecture and regulation.
Taken together, the review frames inflammasomes and PANoptosomes not as isolated curiosities of innate immunity but as a structurally unified family of molecular decision-making machines whose misregulation underlies a broad spectrum of human disease. As cryo-electron microscopy, cryogenic electron tomography, and single-molecule imaging continue to reveal these assemblies at ever higher resolution in increasingly native contexts, the prospect of precisely targeted anti-inflammatory therapeutics, capable of silencing pathological inflammation while preserving beneficial host defense, moves steadily closer to reality.
Subject of Research: Structural and mechanistic analysis of innate immune sensors that assemble inflammasomes and PANoptosomes
Article Title: Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications
Article References: Upadhyay, S., Nagampalli, R., Resende, S., & Kanneganti, T.-D. (2026). Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications. Cell Research. https://doi.org/10.1038/s41422-026-01287-9
Image Credits: AI Generated
DOI: 10.1038/s41422-026-01287-9
Keywords: innate immunity, inflammasome, PANoptosis, PANoptosome, NLRP3, ZBP1, ASC, caspase-1, gasdermin D, pyroptosis, structural biology, anti-inflammatory therapeutics
Cite Scienmag News
APA
MLA
Chicago
Jason Bradley. (September 12, 2026). Innate Immune Sensors in Focus: Structural Insights into Inflammasomes and PANoptosomes Open New Therapeutic Avenues. Scienmag. https://scienmag.com/innate-immune-sensors-in-focus-structural-insights-into-inflammasomes-and-panoptosomes-open-new-therapeutic-avenues/
Jason Bradley. “Innate Immune Sensors in Focus: Structural Insights into Inflammasomes and PANoptosomes Open New Therapeutic Avenues.” Scienmag, 12 September 2026, https://scienmag.com/innate-immune-sensors-in-focus-structural-insights-into-inflammasomes-and-panoptosomes-open-new-therapeutic-avenues/. Accessed 12 September 2026.
Jason Bradley. “Innate Immune Sensors in Focus: Structural Insights into Inflammasomes and PANoptosomes Open New Therapeutic Avenues.” Scienmag. September 12, 2026. https://scienmag.com/innate-immune-sensors-in-focus-structural-insights-into-inflammasomes-and-panoptosomes-open-new-therapeutic-avenues/
Copy citation
Download RIS
Tags: anti-inflammatory therapeuticsASCcaspase-1cryo-electron microscopy in immune researchdanger signal recognitiongasdermin Dimmunotherapy developmentinflammasomeinflammasome assembly and functioninflammasome structural biologyinflammatory cell death pathwaysinnate immune sensorsinnate immune system therapeutic targetsinnate immunitymultiprotein signaling complexesNLRP3NLRP3 inflammasome activationPANoptosisPANoptosomePANoptosome mechanismspattern recognition receptorspyroptosisstructural biologyZBP1
